Aqtual, Inc.
Katharine Dilger is an experienced professional in assay development and next-generation sequencing (NGS) product development. Currently serving as the Head of Assay Development at Aqtual, Inc. since March 2022, Katharine previously held various roles at Integrated DNA Technologies from March 2016 to March 2022, including Staff Scientist and Research Scientist III. Prior experience includes positions at Guardant Health, Inc., where responsibilities involved optimizing NGS processes and leading technology transfers, as well as roles at Pall Life Sciences and Zeus Scientific, Inc., focusing on microbial assay products and testing systems, respectively. Katharine's career began at Advanced Control Components as an RF Technician. Academic credentials include a Bachelor of Science degree in Molecular Cell Physiology and Chemistry from Monmouth University.
This person is not in any teams
Aqtual, Inc.
Aqtual, Inc. is a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology. Our mission is to revolutionize the treatment and management of these conditions by bridging the translational gap between groundbreaking research and practical healthcare solutions.